IVA — Inventiva S.A.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1756594 ·
Last close
$5.16
Market Cap
$1.08B
52W High
$6.79
52W Low
$4.78
ADV30
313,897
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Dec 2025 | — | — | — | — | 249,511,000 | 99,312,000 | 278,033,000 |
| Jun 2025 | — | — | — | — | 178,955,000 | 122,076,000 | 187,863,000 |
| Dec 2024 | — | — | — | — | 118,967,000 | 96,563,000 | 225,613,000 |
Balance + Analyst (yfinance extras)
Retained Earnings
$-354,138,000
Inventory
$0
Receivables
$9,121,000
ST Investments
$131,558,000
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
12
Yahoo Snapshot (yfinance, live)
Total Revenue
$6,761,000
EBITDA
$-132,497,000
Free Cash Flow
$-200,711,632
Enterprise Value
$1,184,127,872
Total Cash
$99,839,000
Total Debt
$230,890,000
Shares Out
208,947,924
Trailing EPS
$-2.21
Book Value
$-0.17
ROE
—
ROA
-45.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 4,483,000 | -132,883,000 | -354,138,000 | 249,511,000 | 278,033,000 | — | -104,884,000 |
| Dec 2024 | 9,198,000 | -93,989,000 | -184,212,000 | 118,967,000 | 225,613,000 | — | -85,928,000 |
| Dec 2023 | 17,477,000 | -102,665,000 | -110,426,000 | 69,561,000 | 101,592,000 | — | -81,614,000 |
| Dec 2022 | 12,179,000 | -56,857,000 | -54,274,000 | 116,004,000 | 70,528,000 | — | -44,928,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.91
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CRVS | Corvus Pharmaceuticals, Inc. | $1.08B | $12.83 | — |
| XERS | Xeris Biopharma Holdings, Inc. | $1.08B | $6.26 | — |
| JBIO | Jade Biosciences, Inc. | $1.07B | $21.71 | — |
| MNKD | MANNKIND CORP | $1.09B | $3.53 | — |
| COLL | COLLEGIUM PHARMACEUTICAL, INC | $1.10B | $33.78 | — |
News headlines (Yahoo Finance, 1h cache)
Inventiva Reports 2026 First Quarter Financial Information¹
2026-05-26 20:00 · Yahoo
Inventiva to Present at 2026 Jefferies Global Healthcare Conference
2026-05-21 20:00 · Yahoo
Assessing Inventiva (ENXTPA:IVA) Valuation As Losses Deepen And MASH Trial Progresses
2026-05-21 06:11 · Yahoo
How The Inventiva (ENXTPA:IVA) Story Is Shifting As Analyst Views Grow More Divided
2026-05-20 00:21 · Yahoo
Inventiva to Present Abstracts at the EASL Congress 2026
2026-05-13 06:30 · Yahoo
Inventiva Builds Up Leadership Team Ahead of Potential Commercialization
2026-04-22 22:03 · Yahoo
Inventiva Strengthens Leadership Team Ahead of Expected Phase 3 Data Readout of Lanifibranor
2026-04-22 20:00 · Yahoo
Inventiva announces filing of its 2025 Universal Registration Document and 2025 Annual Report on Form 20-F
2026-04-08 20:00 · Yahoo
How The Inventiva (ENXTPA:IVA) Story Is Shifting With Lanifibranor And Analyst Revisions
2026-04-07 04:32 · Yahoo
Inventiva SA (IVA) (Q4 2025) Earnings Call Highlights: Strategic Milestones and Financial ...
2026-04-02 01:01 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.